Synapse - David Hyman

Results (354)

Novel activating mutations in CSF1R and additional kinases with therapeutic implications in histiocytic neoplasms

Meeting Abstract

Durham, B.; Picarsic, J.; Lopez-Rodrigo, E.; Hyman, D.; Diamond, E.; Abdel-Wahab, O.
Laboratory Investigation (2019)

Activity of larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase, in TRK fusion breast cancers

Meeting Abstract

Meric-Bernstam, F.; Shukla, N.; Peled, N.; Landman, Y.; Onitilo, A.; Montez, S.; Ku, N. C.; Hyman, D. M.; Drilon, A.; Hong, D. S.
Cancer Research (2019)

Fulltext@MSK | Save

Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer

Meeting Abstract

Smyth, L. M.; Saura, C.; Piha-Paul, S. A.; Lu, J.; Mayer, I. A.; Brufksy, A. M.; Spanggaard, I.; Arnedos, M.; Cutler, R. E.; Hyman, D. M.
Annals of Oncology (2019)

Fulltext@MSK | Save

Treating HER2-mutant advanced biliary tract cancer with neratinib: Benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket; trial

Meeting Abstract

Harding, J.; Cleary, J.; Shapiro, G.; Braña, I.; Moreno, V.; Quinn, D.; Borad, M.; Loi, S.; Spanggaard, I.; Stemmer, S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: Preliminary results

Meeting Abstract

Matos, I.; Goyal, L.; Cleary, J.; Voss, M.; Oh, D.; Bernstam, F. M.; Ng, C.; Iyer, G.; Ishii, N.; Hu, Y.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden